{
    "organizations": [],
    "uuid": "50912b40ff8f567f96084f63364777f30d6e410e",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-aurobindo-pharma-says-us-fda-issue/brief-aurobindo-pharma-says-u-s-fda-issued-form-483-with-9-observations-for-cos-unit-idUSFWN1QN05X",
    "ord_in_thread": 0,
    "title": "BRIEF-Aurobindo Pharma Says U.S. FDA Issued Form 483 With 9 Observations for Co's Unit",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 5 (Reuters) - Aurobindo Pharma Ltd:\n* AUROBINDO PHARMA LTD CLARIFIES ON NEWS ITEM ON COâ€™S UNIT 4 GETTING 9 OBSERVATIONS AFTER U.S. FDA INSPECTION\n* U.S. FDA CONDUCTED INSPECTION AT UNIT IV, HYDERABAD; AT END OF INSPECTION, CO WAS ISSUED FORM 483 WITH 9 OBSERVATIONS\n* CO WOULD BE REPLYING TO FDA WITHIN 15 WORKING DAYS Source text - bit.ly/2CZTzED Further company coverage:\n ",
    "published": "2018-03-05T15:37:00.000+02:00",
    "crawled": "2018-03-06T22:33:08.004+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "aurobindo",
        "pharma",
        "ltd",
        "aurobindo",
        "pharma",
        "ltd",
        "clarifies",
        "news",
        "item",
        "co",
        "unit",
        "getting",
        "observation",
        "fda",
        "inspection",
        "fda",
        "conducted",
        "inspection",
        "unit",
        "iv",
        "hyderabad",
        "end",
        "inspection",
        "co",
        "issued",
        "form",
        "observation",
        "co",
        "would",
        "replying",
        "fda",
        "within",
        "working",
        "day",
        "source",
        "text",
        "company",
        "coverage"
    ]
}